Sibyl Wray, MD
Neurology · Knoxville, TNNPI 1881662591
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $234,374 of the $376,540 with a category attached, or 62.2%. 45 manufacturers reported payments, led by Biogen at 51.4% of the total. Reporting peaked in 2019 at $137,843 and has fallen 92.4% since, to $10,441 in 2025. Among neurology clinicians in TN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 802 payments — averaging $469.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biogen$194K
- Sanofi$48K
- E.r. Squibb & Sons, L.L.C.$33K
- EMD Serono, Inc.$25K
- Bristol Myers Squibb$24K
- Genentech USA, Inc.$19K
- plus $34K from 39 others
Across 1,819 payments — averaging $12,798 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$15.5M
- Genentech, Inc.$2.5M
- TG Therapeutics, Inc.$1.7M
- Sanofi$1.5M
- Biogen$739K
- F. Hoffmann-la Roche AG$639K
- plus $710K from 11 others
What the payments were for
- Consulting fees$92,23724%
- Speaking & faculty fees$234,37462%
- Travel & lodging$34,0829%
- Food & beverage$15,7234%
- Education$1240%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$376,540 in reported general payments places this provider in the 95th percentile of 361 neurology providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OcrevusOcrelizumab | 15 | $551,860 |
| Kesimpta PenOfatumumab | 62 | $550,070 |
| AubagioTeriflunomide | 55 | $511,140 |
| VumerityDiroximel Fumarate | 52 | $487,871 |
| TecfideraDimethyl Fumarate | 24 | $229,386 |
| GilenyaFingolimod Hcl | 19 | $196,727 |
| TysabriNatalizumab | 23 | $191,763 |
| BetaseronInterferon Beta-1b | 12 | $114,693 |
| CopaxoneGlatiramer Acetate | 16 | $90,853 |
| Dalfampridine ErDalfampridine | 57 | $44,504 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 14 | $38,101 |
| NuedextaDextromethorphan Hbr/Quinidine | 25 | $36,794 |
| Aimovig AutoinjectorErenumab-Aooe | 15 | $28,859 |
| Glatiramer Acetate | 12 | $18,799 |
| Teriflunomide | 12 | $6,712 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| BiogenVumerity, Tecfidera, Tysabri | $193,555 | $909,02099 claims |
| Genentech, Inc.Ocrevus | $4,267 | $551,86015 claims |
| SanofiAubagio | $47,558 | $511,14055 claims |
| NovartisGilenya | $4,092 | $196,72719 claims |
| Teva Pharmaceuticals USA, Inc.Copaxone | $289 | $90,85316 claims |
| Grifols USA, LLCGamunex-C | $20 | $38,10114 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $547 | $36,79425 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 361 neurology providers in Tennessee.
Other neurology in Knoxville
- David BrandesKnoxville$412K
- Joseph VaughanKnoxville$177K
- Rosanne BarkerKnoxville$40K
- Randall TrudellKnoxville$39K
- Michelle BrewerKnoxville$37K
- Samuel HunterSpring Hill$676K
- Harold MosesNashville$438K
- Lucas ElijovichMemphis$415K
- Christine HagenAlcoa$371K
- Mark LedouxMemphis$352K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.